$123.03
0.32% yesterday
Nasdaq, May 28, 10:00 pm CET
ISIN
US64125C1099
Symbol
NBIX

Neurocrine Biosciences, Inc. Stock price

$123.03
+16.57 15.56% 1M
-3.56 2.81% 6M
-13.47 9.87% YTD
-17.45 12.42% 1Y
+29.93 32.15% 3Y
+2.81 2.34% 5Y
+80.27 187.72% 10Y
Nasdaq, Closing price Wed, May 28 2025
+0.39 0.32%
ISIN
US64125C1099
Symbol
NBIX
Sector
Industry

Key metrics

Market capitalization $12.18b
Enterprise Value $11.23b
P/E (TTM) P/E ratio 41.29
EV/FCF (TTM) EV/FCF 22.82
EV/Sales (TTM) EV/Sales 4.66
P/S ratio (TTM) P/S ratio 5.05
P/B ratio (TTM) P/B ratio 4.80
Revenue growth (TTM) Revenue growth 21.73%
Revenue (TTM) Revenue $2.41b
EBIT (operating result TTM) EBIT $501.40m
Free Cash Flow (TTM) Free Cash Flow $492.20m
Cash position $943.50m
EPS (TTM) EPS $2.98
P/E forward 30.74
P/S forward 4.53
EV/Sales forward 4.18
Short interest 6.05%
Show more

Is Neurocrine Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Neurocrine Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Neurocrine Biosciences, Inc. forecast:

23x Buy
85%
4x Hold
15%

Analyst Opinions

27 Analysts have issued a Neurocrine Biosciences, Inc. forecast:

Buy
85%
Hold
15%

Financial data from Neurocrine Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
2,413 2,413
22% 22%
100%
- Direct Costs 36 36
8% 8%
1%
2,377 2,377
22% 22%
99%
- Selling and Administrative Expenses 1,041 1,041
17% 17%
43%
- Research and Development Expense 835 835
43% 43%
35%
530 530
8% 8%
22%
- Depreciation and Amortization 29 29
27% 27%
1%
EBIT (Operating Income) EBIT 501 501
7% 7%
21%
Net Profit 306 306
17% 17%
13%

In millions USD.

Don't miss a Thing! We will send you all news about Neurocrine Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Neurocrine Biosciences, Inc. Stock News

Neutral
GlobeNewsWire
about 12 hours ago
Tokyo, Japan and Cambridge, UK, 29 May 202 5 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes that Neurocrine Biosciences, Inc. announced that it had presented new positive data from the Phase 2 study of NBI-1117568 in adults with schizophrenia at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting in Scottsdale, Arizona.
Neutral
PRNewsWire
about 16 hours ago
SAN DIEGO , May 28, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of data from the Phase 2 study of NBI-1117568 in adults with schizophrenia, which showed a significant improvement in symptoms and overall severity and highlighted new data on the safety and tolerability of the treatment. NBI-1117568 is the first and only investigational oral mu...
Neutral
Investors Business Daily
10 days ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
More Neurocrine Biosciences, Inc. News

Company Profile

Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.

Head office United States
CEO Kyle Gano
Employees 1,800
Founded 1992
Website www.neurocrine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today